Patents by Inventor Sylvia Holden

Sylvia Holden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer Treatments with Radiation and Immunocytokines
    Publication number: 20100330029
    Abstract: The present invention is directed to a method for treating tumors and cancer cells by administering an immunocytokine following radiation treatment. This combination of treatments can stimulate an immune response at irradiated and non-irradiated sites, which is useful in eradicating cancer cells that have spread from the site of the primary tumor. In addition, immunocytokines can be administered at a dose that is less that the maximum tolerated dose, which reduces the side effects associated with immunocytokine therapy.
    Type: Application
    Filed: October 21, 2009
    Publication date: December 30, 2010
    Applicant: Merck Patent GmbH
    Inventors: Thomas Wickham, Ulrike Gnad-Vogt, Sylvia Holden, Stephan G. Klinz, Karl-Josef Kallen
  • ENHANCEMENT OF ANTIBODY-CYTOKINE FUSION PROTEIN MEDIATED IMMUNE RESPONSES BY COMBINED TREATMENT WITH IMMUNOCYTOKINE UPTAKE ENHANCING AGENTS
    Publication number: 20100297060
    Abstract: Disclosed are methods and compositions for treating tumors. Disclosed methods and compositions enhance the uptake of immunocytokines into tumors, and are based on a combination of an immunocytokine with an immunocytokine uptake enhancing agent. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.
    Type: Application
    Filed: February 27, 2009
    Publication date: November 25, 2010
    Applicant: MERCK PATENT GMBH
    Inventors: STEPHEN D. GILLIES, YAN LAN, SYLVIA HOLDEN
  • Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
    Patent number: 7517526
    Abstract: Disclosed are methods and compositions for treating tumors. Disclosed methods and compositions enhance the uptake of immunocytokines into tumors, and are based on a combination of an immunocytokine with an immunocytokine uptake enhancing agent. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: April 14, 2009
    Assignee: Merck Patent GmbH
    Inventors: Stephen D. Gillies, Yan Lan, Sylvia Holden
  • Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
    Publication number: 20030049227
    Abstract: Disclosed are methods and compositions for treating tumors. Disclosed methods and compositions enhance the uptake of immunocytokines into tumors, and are based on a combination of an immunocytokine with an immunocytokine uptake enhancing agent. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.
    Type: Application
    Filed: June 29, 2001
    Publication date: March 13, 2003
    Inventors: Stephen D. Gillies, Yan Lan, Sylvia Holden
  • Quinone derivatives
    Patent number: 6433199
    Abstract: The invention relates to a quinone derivative of the following formula: which is capable of converting into two alkylating agents upon bioreduction. Substituents A, B, C, and D are as described herein.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: August 13, 2002
    Assignee: Shionogi BioResearch Corporation
    Inventors: Mitsunori Ono, Keizo Koya, Lijun Sun, Yumiko Wada, Wojciech Wrona, Natalie Dales, Xueliang Tao, Sylvia Holden
  • Bis (haloethyl) aminobenzene derivatives
    Patent number: 6137003
    Abstract: The present invention relates to bis(haloethyl)aminobenzene derivatives featured by having carboxyl-containing moiety and one other moiety at the ortho position with respect to the bis(haloethyl)amino substituent of the benzene ring. The moiety at the ortho position can be alkyl, cycloalkyl, heterocycloalkyl, aryl heteroaryl, alkyl(cycloalkyl), alkyl(heterocycloalkyl), alkyl(heteroaryl), alkyl(aryl), --(--O-alkyl).sub.2-5 or --Y.sup.1 --Y.sup.2 in which Y.sup.1 is O, S, or N(R.sup.5) wherein R.sup.5 is hydrogen or alkyl, and Y.sup.2 is alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroacryl, alkyl(cycloalkyl), alkyl(hetero-cycloalkyl), alkyl(aryl), or alkyl(heteroaryl).
    Type: Grant
    Filed: October 28, 1998
    Date of Patent: October 24, 2000
    Assignee: Shionogi BioResearch
    Inventors: Mitsunori Ono, Keizo Koya, Lijun Sun, Wojciech Wrona, Sylvia Holden, Noriaki Tatsuta
  • Bioreductive cytotoxic agents
    Patent number: 5969133
    Abstract: A compound which consists of a proactive alkylating moiety containing an electron-withdrawing group, a bioreductive moiety containing at least two double bonds, and a linker joining the proactive alkylating moiety and the bioreductive moiety.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: October 19, 1999
    Assignee: Shiongi BioResearch Corp.
    Inventors: Mitsunori Ono, Keizo Koya, Lijun Sun, Yumiko Wada, Wojciech Wrona, Natalie Dales, Xueliang Tao, Sylvia Holden